According to Fleischer, epicutaneous immunotherapy represents a “marathon, not a sprint,” with potential long-term benefits when started young.
David Fleischer, MD
Advertisement
David Fleischer, MD, professor of pediatrics at Children’s Hospital Colorado and global principal investigator of the VITESSE study.
Articles by David Fleischer, MD
David Fleischer, MD, says phase 3 VITESSE results show the Viaskin peanut patch offers a safe, practical desensitization option for young children with peanut allergy.
Advertisement
Latest Updated Articles
How Viaskin could expand options for families managing peanut allergy, with David Fleischer, MDPublished: January 7th 2026 | Updated:
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
AAP publishes 2026 childhood and adolescent immunization schedule
2
Genomic sequencing may transform newborn screening
3
ELEVIDYS demonstrates sustained functional benefit through 3 years in ambulatory Duchenne muscular dystrophy
4
Kathryn M. Stephenson, MD, MA, discusses GLP-1 RA decisions for pediatric obesity
5